Do analysts prefer CVAC or ABCL?

AbCellera Biologics has a consensus target price of $13.89, suggesting a potential upside of 10.14%. Given AbCellera Biologics' stronger consensus rating and higher probable upside, analysts plainly believe AbCellera Biologics is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AbCellera Biologics 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.70

Do analysts prefer RLAY or CVAC?

Relay Therapeutics currently has a consensus price target of $25.92, suggesting a potential upside of 49.29%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Relay Therapeutics is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Relay Therapeutics 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 2.93 CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, RLAY or CVAC?

CureVac has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Relay Therapeutics $15.35M 247.84 -$276.48M -$1.57 N/A CureVac $70.74M 14.78 $175.50M $0.72 6.47

Do analysts rate TLX or CVAC?

Telix Pharmaceuticals currently has a consensus price target of $20.50, indicating a potential upside of 87.73%. Given Telix Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Telix Pharmaceuticals is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telix Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, TLX or CVAC?

CureVac has lower revenue, but higher earnings than Telix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 4.62 -$7.12M N/A N/A CureVac $70.74M 14.78 $175.50M $0.72 6.47

Do analysts prefer LEGN or CVAC?

Legend Biotech presently has a consensus target price of $55.07, indicating a potential upside of 208.01%. Given Legend Biotech's stronger consensus rating and higher possible upside, research analysts plainly believe Legend Biotech is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Legend Biotech 1 Sell rating(s) 5 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.53 CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is LEGN or CVAC more profitable?

CureVac has a net margin of 199.92% compared to Legend Biotech's net margin of -7.21%. Legend Biotech's return on equity of -8.71% beat CureVac's return on equity. Company Net Margins Return on Equity Return on Assets Legend Biotech -7.21% -8.71% -5.40% CureVac 199.92% -23.03% -19.09%

Do analysts recommend VKTX or CVAC?

Viking Therapeutics currently has a consensus target price of $99.44, suggesting a potential upside of 273.15%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Viking Therapeutics is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viking Therapeutics 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.75 CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

CureVac (CVAC) Competitors

$4.66 0.00 (0.00%)

As of 10/12/2026

Compare

CVAC vs. ABCL, RLAY, TLX, LEGN, and VKTX

Should you buy CureVac stock or one of its competitors? CureVac's main competitors and comparable companies include AbCellera Biologics (ABCL), Relay Therapeutics (RLAY), Telix Pharmaceuticals (TLX), Legend Biotech (LEGN), and Viking Therapeutics (VKTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does CureVac compare to AbCellera Biologics?

CureVac (NASDAQ:CVAC) and AbCellera Biologics (NASDAQ:ABCL) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

In the previous week, AbCellera Biologics had 9 more articles in the media than CureVac. MarketBeat recorded 9 mentions for AbCellera Biologics and 0 mentions for CureVac. AbCellera Biologics' average media sentiment score of 0.38 beat CureVac's score of 0.00 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company	Overall Sentiment
CureVac	Neutral
AbCellera Biologics	Neutral

CureVac has a net margin of 199.92% compared to AbCellera Biologics' net margin of -248.83%. AbCellera Biologics' return on equity of -17.49% beat CureVac's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
AbCellera Biologics	-248.83%	-17.49%	-12.36%

CureVac has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market.

CureVac has higher earnings, but lower revenue than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
AbCellera Biologics	$75.13M	51.46	-$146.41M	-$0.54	N/A

17.3% of CureVac shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 2.2% of CureVac shares are owned by insiders. Comparatively, 28.4% of AbCellera Biologics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

AbCellera Biologics has a consensus target price of $13.89, suggesting a potential upside of 10.14%. Given AbCellera Biologics' stronger consensus rating and higher probable upside, analysts plainly believe AbCellera Biologics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AbCellera Biologics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.70

Summary

AbCellera Biologics beats CureVac on 12 of the 17 factors compared between the two stocks.

How does CureVac compare to Relay Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and CureVac (NASDAQ:CVAC) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

In the previous week, Relay Therapeutics had 11 more articles in the media than CureVac. MarketBeat recorded 11 mentions for Relay Therapeutics and 0 mentions for CureVac. Relay Therapeutics' average media sentiment score of 0.66 beat CureVac's score of 0.00 indicating that Relay Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Relay Therapeutics	Positive
CureVac	Neutral

Relay Therapeutics currently has a consensus price target of $25.92, suggesting a potential upside of 49.29%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Relay Therapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CureVac has a net margin of 199.92% compared to Relay Therapeutics' net margin of 0.00%. CureVac's return on equity of -23.03% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-42.27%	-38.67%
CureVac	199.92%	-23.03%	-19.09%

Relay Therapeutics has a beta of 1.72, indicating that its stock price is 72% more volatile than the broader market. Comparatively, CureVac has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market.

CureVac has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	247.84	-$276.48M	-$1.57	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

97.0% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 5.0% of Relay Therapeutics shares are owned by insiders. Comparatively, 2.2% of CureVac shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Relay Therapeutics beats CureVac on 9 of the 17 factors compared between the two stocks.

How does CureVac compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and CureVac (NASDAQ:CVAC) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

In the previous week, Telix Pharmaceuticals had 7 more articles in the media than CureVac. MarketBeat recorded 7 mentions for Telix Pharmaceuticals and 0 mentions for CureVac. Telix Pharmaceuticals' average media sentiment score of 0.09 beat CureVac's score of 0.00 indicating that Telix Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Telix Pharmaceuticals	Neutral
CureVac	Neutral

CureVac has lower revenue, but higher earnings than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.62	-$7.12M	N/A	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

Telix Pharmaceuticals currently has a consensus price target of $20.50, indicating a potential upside of 87.73%. Given Telix Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Telix Pharmaceuticals is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CureVac has a net margin of 199.92% compared to Telix Pharmaceuticals' net margin of 0.00%. Telix Pharmaceuticals' return on equity of 0.00% beat CureVac's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
CureVac	199.92%	-23.03%	-19.09%

17.3% of CureVac shares are owned by institutional investors. 2.2% of CureVac shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Telix Pharmaceuticals has a beta of -0.17, meaning that its share price is 117% less volatile than the broader market. Comparatively, CureVac has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

Summary

Telix Pharmaceuticals beats CureVac on 8 of the 14 factors compared between the two stocks.

How does CureVac compare to Legend Biotech?

Legend Biotech (NASDAQ:LEGN) and CureVac (NASDAQ:CVAC) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

Legend Biotech presently has a consensus target price of $55.07, indicating a potential upside of 208.01%. Given Legend Biotech's stronger consensus rating and higher possible upside, research analysts plainly believe Legend Biotech is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.53
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Legend Biotech had 9 more articles in the media than CureVac. MarketBeat recorded 9 mentions for Legend Biotech and 0 mentions for CureVac. CureVac's average media sentiment score of 0.00 beat Legend Biotech's score of -0.02 indicating that CureVac is being referred to more favorably in the news media.

Company	Overall Sentiment
Legend Biotech	Neutral
CureVac	Neutral

70.9% of Legend Biotech shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by insiders. Comparatively, 2.2% of CureVac shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Legend Biotech has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market. Comparatively, CureVac has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market.

CureVac has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	3.37	-$296.80M	-$0.25	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

CureVac has a net margin of 199.92% compared to Legend Biotech's net margin of -7.21%. Legend Biotech's return on equity of -8.71% beat CureVac's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-7.21%	-8.71%	-5.40%
CureVac	199.92%	-23.03%	-19.09%

Summary

Legend Biotech beats CureVac on 8 of the 15 factors compared between the two stocks.

How does CureVac compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and CureVac (NASDAQ:CVAC) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

CureVac has a net margin of 199.92% compared to Viking Therapeutics' net margin of 0.00%. CureVac's return on equity of -23.03% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-94.56%	-82.75%
CureVac	199.92%	-23.03%	-19.09%

Viking Therapeutics has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market. Comparatively, CureVac has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market.

CureVac has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

In the previous week, Viking Therapeutics had 7 more articles in the media than CureVac. MarketBeat recorded 7 mentions for Viking Therapeutics and 0 mentions for CureVac. Viking Therapeutics' average media sentiment score of 0.37 beat CureVac's score of 0.00 indicating that Viking Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Viking Therapeutics	Neutral
CureVac	Neutral

76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 5.3% of Viking Therapeutics shares are owned by insiders. Comparatively, 2.2% of CureVac shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Viking Therapeutics currently has a consensus target price of $99.44, suggesting a potential upside of 273.15%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Viking Therapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Viking Therapeutics and CureVac tied by winning 8 of the 16 factors compared between the two stocks.

Get CureVac News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CVAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CVAC vs. The Competition

Export

Metric	CureVac	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.05B	$3.93B	$7.27B	$13.21B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	6.47	10.78	202.90	19.69
Price / Sales	14.78	1,146.43	561.48	81.34
Price / Cash	4.73	118.50	77.16	53.04
Price / Book	1.39	16.70	10.61	6.03
Net Income	$175.50M	-$22.69M	$3.50B	$380.34M
7 Day Performance	N/A	-4.43%	-2.89%	-2.34%
1 Month Performance	N/A	-12.49%	-7.37%	-5.31%
1 Year Performance	-13.06%	7.63%	3.00%	-2.94%

CureVac Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CVAC CureVac	N/A	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880
ABCL AbCellera Biologics	1.8393 of 5 stars	$13.24 -3.9%	$13.38 +1.0%	+122.4%	$4.04B	$66.17M	N/A	562	Analyst Upgrade
RLAY Relay Therapeutics	2.4197 of 5 stars	$18.33 -5.5%	$25.92 +41.4%	+176.9%	$4.01B	$10.35M	N/A	192
TLX Telix Pharmaceuticals	4.3715 of 5 stars	$10.81 -0.7%	$20.50 +89.7%	+14.5%	$3.67B	$803.79M	N/A	1,184
LEGN Legend Biotech	2.7426 of 5 stars	$18.92 +0.8%	$55.79 +194.9%	-45.6%	$3.66B	$1.27B	N/A	2,965	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CVAC) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CureVac (CVAC) Competitors

CVAC vs. ABCL, RLAY, TLX, LEGN, and VKTX

How does CureVac compare to AbCellera Biologics?

Summary

How does CureVac compare to Relay Therapeutics?

Summary

How does CureVac compare to Telix Pharmaceuticals?

Summary

How does CureVac compare to Legend Biotech?

Summary

How does CureVac compare to Viking Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVAC vs. The Competition

CureVac Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CureVac (CVAC) Competitors

CVAC vs. ABCL, RLAY, TLX, LEGN, and VKTX

How does CureVac compare to AbCellera Biologics?

Does the media favor CVAC or ABCL?

Is CVAC or ABCL more profitable?

Which has more risk & volatility, CVAC or ABCL?

Which has higher valuation & earnings, CVAC or ABCL?

Do institutionals and insiders have more ownership in CVAC or ABCL?

Do analysts prefer CVAC or ABCL?

Summary

How does CureVac compare to Relay Therapeutics?

Does the media prefer RLAY or CVAC?

Do analysts prefer RLAY or CVAC?

Is RLAY or CVAC more profitable?

Which has more volatility and risk, RLAY or CVAC?

Which has preferable valuation & earnings, RLAY or CVAC?

Do institutionals and insiders hold more shares of RLAY or CVAC?

Summary

How does CureVac compare to Telix Pharmaceuticals?

Does the media prefer TLX or CVAC?

Which has better earnings and valuation, TLX or CVAC?

Do analysts rate TLX or CVAC?

Is TLX or CVAC more profitable?

Do institutionals & insiders hold more shares of TLX or CVAC?

Which has more volatility & risk, TLX or CVAC?

Summary

How does CureVac compare to Legend Biotech?

Do analysts prefer LEGN or CVAC?

Does the media refer more to LEGN or CVAC?

Do insiders & institutionals believe in LEGN or CVAC?

Which has more risk & volatility, LEGN or CVAC?

Which has stronger valuation & earnings, LEGN or CVAC?

Is LEGN or CVAC more profitable?

Summary

How does CureVac compare to Viking Therapeutics?

Is VKTX or CVAC more profitable?

Which has more risk & volatility, VKTX or CVAC?

Which has higher valuation and earnings, VKTX or CVAC?

Does the media favor VKTX or CVAC?

Do institutionals & insiders hold more shares of VKTX or CVAC?

Do analysts recommend VKTX or CVAC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVAC vs. The Competition

CureVac Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools